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Abstract
Aims: To investigate the regulation of cannabinoid receptors CB1 and
CB2 on immune cells by pro-inflammatory cytokines and its potential rele-
vance to the inflammatory neurological disease, multiple sclerosis (MS).
CB1 and CB2 signalling may be anti-inflammatory and neuroprotective
in neuroinflammatory diseases. Cannabinoids can suppress inflammatory
cytokines but the effects of these cytokines on CB1 and CB2 expression
and function are unknown.
Methods: Immune cells from peripheral blood were obtained from healthy
volunteers and patients with MS. Expression of CB1 and CB2 mRNA in
whole blood cells, peripheral blood mononuclear cells (PBMC) and T cells
was determined by quantitative real-time polymerase chain reaction
(qRT-PCR). Expression of CB1 and CB2 protein was determined by flow
cytometry. CB1 and CB2 signalling in PBMC was determined by Western
blotting for Erk1/2.
Results: Pro-inflammatory cytokines IL-1b, IL-6 and TNF-a (the latter
likely NF-jB dependently) can upregulate CB1 and CB2 on human whole
blood and peripheral blood mononuclear cells (PBMC). We also demon-
strate upregulation of CB1 and CB2 and increased IL-1b, IL-6 and TNF-a
mRNA in blood of patients with MS compared with controls.
Conclusion: The levels of CB1 and CB2 can be upregulated by inflamma-
tory cytokines, which can explain their increase in inflammatory condi-
tions including MS.
Keywords cannabinoid receptor 1, cannabinoid receptor 2, inflammatory
cytokines, multiple sclerosis, regulation.
Activation of cannabinoid receptors, CB1 and CB2 by
endocannabinoids or exogenous ligands can suppress
inflammation (Tanasescu & Constantinescu 2010). The
endocannabinoid (EC) system consists of the G-protein-
coupled receptors CB1 and CB2, the endogenous ligands
such as anandamide and 2-arachidonylglycerol and
the synthesizing and metabolizing enzymes (Alexander
& Kendall 2007). Exogenous cannabinoid compounds
such as phytocannabinoids D9 tetrahydrocannabinol
and cannabidiol have immunomodulatory properties
(Tanasescu & Constantinescu 2010). They inhibit
pro-inflammatory cytokines (Klein et al. 2000);
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(Jean-Gilles et al. 2010), suppress T-cell proliferation
(Katona et al. 2005), induce T-cell apoptosis (Rieder
et al. 2010) and reduce migration and adhesion of
immune cells. CB receptors are expressed on immune
cells including B cells, T cells, neutrophils and NK
cells, with CB2 levels known to be higher than those
of CB1 (Galiegue et al. 1995). Their widespread loca-
tion in the immune system allows CB receptor activa-
tion to regulate cytokine levels.
Both CB receptors are also expressed in CNS cells
such as neurones, oligodendrocytes, astrocytes and
microglia (Molina-Holgado et al. 2002, Sheng et al.
2005, Stella 2009, Pertwee 2010). All these cells can
secrete inflammatory mediators that are implicated in
the pathogenesis of neuro-inflammatory and neurode-
generative diseases such as multiple sclerosis (MS)
(Hemmer et al. 2006). MS is a chronic inflammatory
disease of the CNS white and grey matter which is
characterized by demyelination, axonal injury and gli-
osis (Compston & Coles 2008). Inflammatory cyto-
kines such as tumour necrosis factor (TNF)-a,
interleukin (IL)-1b and IL-6 are elevated in lesions,
cerebrospinal fluid and blood of patients with MS
(Kahl et al. 2002, Filion et al. 2003, Kleine et al.
2003, Malamud et al. 2003). These cytokines are
thought to play a role both in the CNS and in the
periphery in neuro-inflammatory disease including MS
(Compston & Coles 2008).
Neuroprotective and immunomodulatory effects of
cannabinoids have been demonstrated in the animal
model of MS, experimental autoimmune encephalo-
myelitis (EAE) (Pryce et al. 2003) (Arevalo-Martin
et al. 2003). Beneficial effects were associated with
diminished CNS mRNA expression of pro-inflamma-
tory cytokines (Croxford & Miller 2003). Cannabi-
noids have also shown symptomatic benefit in human
MS clinical trials (Pertwee 2002, Zajicek et al. 2003,
Kavia et al. 2010, Rog 2010) where reduced pain,
sleep disturbance, bladder overactivity, tremor and
spasticity have been observed.
Although CB signalling and the regulation of cyto-
kines by cannabinoids are well documented (De Jesus
et al. 2006, Rubio-Araiz et al. 2008), only a few
recent studies, in rodents mostly, have looked at the
effects of inflammatory cytokines on the cannabinoid
system. An increase in interferon (IFN)-c modulated
microglial CB2 receptors in neuropathic pain and MS
mouse models (Maresz et al. 2005, Racz et al. 2008).
Also, CB2 upregulation in chronic EAE correlated
highly with the production of pro-inflammatory cyto-
kines (Lorıa et al. 2008). CB1 receptors were also
upregulated by the Th2 cytokine IL-4 (which downre-
gulates both Th1 and Th17 cytokines involved in the
pathogenesis of MS and EAE) and by cannabinoids
themselves in human T lymphocytes (B€orner et al.
2007, Borner et al. 2008) while IFN-c was not shown
to have any effect on CB1 expression by human
T cells (B€orner et al. 2007). In other studies in EAE,
CB2 was shown to be upregulated in a progressive
manner on specific post-immunization days in the
presence of cytokines IFN-c, IL-17, IL-4, IL-10, IL-1b,
IL-6 and TNF-a (Lou et al. 2011), while CB1 receptor
expression was downregulated on same days (Lou
et al. 2012). Those studies suggest that manipulation
of CB and CB receptors may have therapeutic value in
MS.
In this study, we investigate the effects of the above
pro-inflammatory cytokines on the expression of CB1
and CB2 on immune cells from both healthy subjects
and patients with MS. We also show an upregulation
of mRNA for CB receptors and for TNF-a, IL-1 and
IL-6 in peripheral blood of people with MS compared
to healthy controls.
Materials and methods
Donors and RNA extraction from blood
The study conforms with guidelines for Acta Physio-
logica (Persson 2013). Whole blood was obtained
from 20 patients with MS (relapsing remitting,
n = 12; secondary progressive, n = 6; and primary
progressive, n = 2). These included 13 females and 7
males aged 28–64 years; mean Expanded Disability
Status Scale (EDSS) score (Kurtzke 1983) = 4.6;
range, 2.0–7.5. The patients were free of MS-specific
immunomodulatory, immunosuppressive or monoclo-
nal antibody therapies for at least 2 months.
Nineteen age- and gender-matched healthy volun-
teer subjects (14 females and 5 males, aged
27–62 years), not taking medicines, were used as con-
trols. Peripheral blood mononuclear cells (PBMC)
were isolated from heparinized whole blood obtained
from healthy adult donors (8 females, 8 males; age
21–56 years) by density gradient centrifugation. Cells
were resuspended in 10% FCS/RPMI, transferred to
24-well plates at 1 9 106/well and unstimulated or
stimulated with IL-6 (100 ng mL1), IL-1b (100 ng
mL1) or TNF-a (25 ng mL1) (Peprotech, Lon-
don, UK) in the absence or the presence of the
NF-jB inhibitor SN50 (18 lM) (Calbiochem, Notting-
ham, UK) and incubated at 37 °C (5% CO2) for
18 h.
In a separate experiment comparing MS and control
PBMC responses to pro-inflammatory cytokines,
PBMC were isolated as above from 12 patients with
MS different from the above (10 females, 2 males;
mean  SD age 48.3  13.8 years) and 12 healthy
controls (7 females, 5 males, males; mean  SD age
42.8  10.2 years). Five were not receiving and 7
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were receiving disease-modifying treatment (5 inter-
feron, 2 glatiramer acetate). Frozen PBMC were
thawed and unstimulated or stimulated with IL-6,
IL-1b or TNF-a (100 pg mL1). Expression of CB1
and CB2 mRNA and protein was analysed by qRT-
PCR and flow cytometry respectively.
Generation of polyclonally activated T cells (T-cell blasts)
Phytohemagglutinin (PHA)/IL-2-stimulated T cells were
obtained from PBMC as shown before (Fahey et al.
2007) and after 24-h serum starvation stimulated with
IL-6, IL-1b (100 ng mL1) or TNF-a (25 ng mL1) for
a further 18 h.
RNA extraction and quantification
This was performed as previously described (Fahey
et al. 2007, Jean-Gilles et al. 2009).
Whole blood preparation for flow cytometry
0.5 mL of heparinized venous blood was unstimu-
lated or stimulated with IL-1b, IL-6 (100 ng mL1)
or TNF-a (25 ng mL1) and incubated for 18 h
(37 °C; 5%CO2). 2 mmol L
1 EDTA (pH 8) was
added to tubes and incubated for 15 min (RT). Ali-
quotes were exposed to FACS lysing and FACS per-
meabilizing solution (BD Biosciences, Oxford, UK)
and stained with antibodies CB1 [1 : 50] (PA1-745),
CB2 [1 : 50] (PA1-744) (Affinity Bioreagents, Golden,
CO, USA) or control normal rabbit IgG [1 : 40] (Pro-
Sci, Poway, CA, USA), then incubated with PE-conju-
gated goat anti-rabbit IgG [1 : 10] (Invitrogen,
Paisley, UK) and were fixed in 1% formaldehyde/PBS
for flow cytometry (Beckman-Coulter Altra Sorter,
High Wycombe, UK).
Reverse-transcriptase reaction and quantitative real-time
polymerase chain reaction
These studies were performed as previously described
(Fahey et al. 2007) on a Mx4000 or Mx3005 plat-
form (Stratagene, La Jolla, CA, USA). Reaction condi-
tions are available on request. Primer sequences are
shown in Table 1. Beta-2-microglobulin (B2MG)
(PBMC, T cells) and large human ribosomal protein-
PO (RPLPO) (whole blood) were used as housekeep-
ing genes for normalization of data.
mRNA results were based on normalized ratio to
the internal standard expression (RPLPO for blood or
B2MG for PBMC and T cells), and significance
(P ≤ 0.05) in differences between the groups was
determined by t-test and one-way repeated measures
ANOVA.
Intracellular staining and flow cytometry
Peripheral blood mononuclear cells thawed from 12
patients with MS and 12 healthy controls were
unstimulated or stimulated with cytokines then
incubated for 24 h. For some experiments (not
shown), conjugated anti-CD4, CD8 (T cells), CD3-,
-CD14, -CD16 and -CD19 (PBMC) mouse monoclo-
nal antibodies were added. After fixation and permea-
bilization, they were stained with CB1-APC (and
isotype control) and CB2 primary antibody (R&D),
incubated for 30 min and then stained with FITC sec-
ondary antibody and isotype control (R&D). Data
were analysed using WEASEL V3.1.
For T-cell experiments, the same above reagents as
for whole blood were used. CB1 and CB2 protein
abundance was using WINMDI software. Changes in
mean fluorescence intensity [geometric (g) mean] and/
or % of positive cells were calculated by comparing
negative control (no anti-CB1 or CB2 antibodies used),
unstimulated and stimulated (with cytokines) cells.
Positive cells were gated in two-parameter histograms
and/or shifts (increase in mean or median fluorescence
intensity (MFI) were gated within marker M1 for sin-
gle-parameter histograms and averaged across whole
population.
Western blotting
Peripheral blood mononuclear cells were in 2%FCS/
RPMI with or without cytokines, CB1/CB2 agonist
HU-210 (Tocris, Bristol, UK) [100 nM] in the presence
or absence of CB1 antagonist SR141716A (SR1, rimo-
nabant) and CB2 antagonist SR144528 (SR2)
[300 nM] (gifts from Sanofi, Guildford, UK) and were
centrifuged for 10 min (300 g, 4 °C). The supernatant
was discarded and lysis buffer [with 20 mmol L1
Table 1 Primers used for PCR
B2MG for 50-CTC CGT GGC CTT AGC TGT G-30
B2MG rev 50-TTT GGA GTA CGC TGG ATA GCC T-30
RPLPO for 50-CCA CGC TGC TGA ACA TGC T-30
RPLPO rev 50-TCG AAC ACC TGC TGG ATG AC-30
CB1 for 5
0-CTG GAA CTG CGA GAA ACT G-30
CB1 rev 5
0-CGC ATA CAC GAT GAA CAG AAG-30
CB2 for 5
0-GCC TCT TCC CAA TTT AAA CAA C-30
CB2 rev 5
0-AGT CAG TCC CAA CAC TCA TC-30
IL-6 for 50-TCA ATG AGG AGA CTT GCC TG-30
IL-6 rev 50-GAT GAG TTG TCA TGT CCT GC-30
IL-1b for 50-GGA TAT GGA GCA ACA AGT GG-30
IL-1b rev 50-ATG TAC CAG TTG GGG AAC TG-30
TNF-a for 50-ACA AGC CTG TAG CCC ATG TT-30
TNF-a rev 50-AAA GTA GAC CTG CCC AGA CT-30
for, forward; rev, reverse.
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Tris, 1 mmol L1 EGTA and protease inhibitor
(P8340; Sigma, Gillingham, UK)] was added. Samples
were homogenized for 30 min (4 °C) and supernatant
extracted. To quantify protein, Lowry test was con-
ducted for homogenates and human recombinant CB1
and CB2 proteins (Axxora, UK) used as positive con-
trols, and protein was equally loaded onto gels. 29
solubilization buffer [containing Tris (20 mmol L1)
(Invitrogen), glycerol, sodium dodecyl sulphate (10%)
(SDS), b-mercaptoethanol and bromophenol blue
(Sigma)] was added [1 : 2], and samples were heated
to 100 °C for 5 min. Proteins (20 lg) were loaded
onto 10% SDS gels and resolved by SDS-polyacryl-
amide gel electrophoresis with a standard marker lad-
der of known molecular weights run alongside
(45 min, 200 V). Following transfer onto nitrocellu-
lose membranes (Amersham Biosciences, Little Chal-
font, UK) (60 min, 100 V, 4 °C) and staining with
Ponceau S (Sigma), blots were blocked in 1 g/20 mL
non-fat dry milk in 0.1% Tris-buffered saline–Tween
20 (pH 7.6) for 60 min. Separated membranes were
incubated overnight (4 °C) with anti-CB1 (1 : 500),
anti-CB2 (1 : 1000) (Affinity Bioreagents), total or
phosphorylated (p)-mitogen-activated protein kinase
(MAPK) 42/44 (Erk1/2) (1 : 1000) antisera (Cell Sig-
nalling Biotechnology, Hitchin, UK). Blots were then
washed and incubated with secondary antibody horse-
radish peroxidase-conjugated goat anti-rabbit IgG
(Amersham Biosciences) in blocking buffer (1 : 2000)
for 60 min (RT) and reprobed with b-actin (1 : 4000)
antibody (Abcam, Cambridge, UK) as a loading con-
trol using enhanced chemoluminescent reagents, hy-
perfilm (Amersham) and Kodak reagents for
development. Specific immunoreactive bands were
analysed using a Bio-Rad GS-710 imaging scanning
densitometer. Protein differences between samples
were analysed based on optical density (OD) of each
band and by two-tailed t-test with P ≤ 0.05. Differ-
ences were explored using one-way repeated measure-
ments ANOVA.
Results
CB1 and CB2 expression in cytokine-stimulated whole
blood, PBMC and PHA/IL-2 induced T cells of normal
subjects
The effects of IL-6, IL-1b and TNF-a on CB1 and CB2
receptor gene expression in whole blood, PBMC and
T cells are shown in Figure 1. TNF-a significantly
induced CB1 and CB2 mRNA levels in whole blood
(P = 0.02, P = 0.01), T cells (P = 0.04, P = 0.04) and
PBMC (P = 0.01, P = 0.04) compared to unstimulated
cells. In each cell population, the expression of CB
Figure 1 CB1 and CB2 mRNA expres-
sion in whole blood, T cells and PBMC.
Cytokine stimulation was with IL-6
[100 ng mL1], IL-1b [100 ng mL1]
and TNF-a [25 ng mL1] mRNA levels
for CB1 (left) and CB2 (right) (arbitrary
units) are presented as mean  SEM
normalized to RPLPO in whole blood
and to B2MG in T cells and PBMC. t-
test for independent samples:
* = P < 0.05; **= P < 0.025; n = 4–5
experiments per condition.
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receptor mRNA levels induced by TNF-a was 2–3
times higher than levels induced by IL-6 and IL-1b.
Although IL-1b and IL-6 significantly increased CB1
(P = 0.04, P = 0.04) and CB2 (P = 0.03, P = 0.02)
mRNA levels in whole blood, induction by these cyto-
kines in T cells did not reach significance. In PBMC, a
non-significant increase was noted for CB2 (P = 0.06
for IL-6; P = 0.07 for IL-1b) and for CB1 (P = 0.12
for IL-6; P = 0.19 for IL-1b). These differences may
reflect a direct or indirect contribution of CB mRNA
induction in polymorphonuclear leucocytes.
The effects of IL-6, IL-1b and TNF-a on the CB1
and CB2 receptor at the protein level assessed using
flow cytometry are shown in Figure 2. Although all
three pro-inflammatory cytokines increased CB1 and
CB2 protein expression levels, stimulation with TNF-a
induced higher levels than IL-6 or IL-1b in whole
blood and PBMC (Fig. 2a,b). CB1 and CB2 immunop-
ositivity in whole blood gated for monocytes/lympho-
cytes was confirmed to be increased by TNF-a (CB1
MFI = 973  243, P = 0.001 and CB2 MFI = 206 
56, P = 0.02) when compared to unstimulated samples
(MFI = 42.1  14.1). CB1 protein MFI was also
increased in whole blood stimulated with IL-1b
(317.4  64.5, P = 0.009) and IL-6 (594.6  130.8,
P = 0.005). CB2 protein MFI induced by IL-1b showed
a non-significant increase (81.5  20.4, P = 0.06), and
with IL-6, it was significantly increased (106.3  28.7,
P = 0.05) (Fig. 2a). PBMC stimulated with cytokines
showed increases in CB1 (MFI: TNF-a = 84.9  17.8;
P = 0.02); IL-6 (49.1  1.1; P = 0.04); IL-1b
(32.1  7.0; P = 0.04). CB2 protein levels (MFI for
TNF-a = 13.5  4.0; P = 0.08; IL-6: 11.9  3.0;
P = 0.09; IL-1b: 10.5  2.9; P = 0.12) only showed
an insignificant increase compared to unstimulated
(MFI = 9.0  2.7) samples (Fig. 2b). CB receptor pro-
tein expression on T cells showed similar regulation by
cytokines to that of PBMC (data not shown).
MAPK (Erk1/2) activation in HU-210-stimulated PBMC
To confirm that CB receptors were functional in
PBMC, HU-210 (100 nM), a non-selective CB1 and
CB2 receptor agonist, was used to activate them.
HU-210 was chosen due to its potency in preference
to weaker selective agonists (Alexander & Kendall
2007). HU-210-stimulated PBMC showed a transient
enhancement of pMAPK42/44 levels (23% increase;
P = 0.03) compared to control (FCS 2%; ODavg =
0.22  0.04) to peak at 15 min (Fig. 3) although no
significant increase in total MAPK was observed.
Immunoreactivity of p42 was more prominent than
p44. Beta-actin immunoreactivity was unchanged.
MAPK (Erk1/2) activation in cytokine-stimulated PBMC
Total and phosphorylated (p)MAPK42/44 immunore-
activity were also assessed in cytokine-stimulated
PBMC, with or without exposure to the cannabinoid
receptor antagonists SR 141716 and SR 144528 (SR1
and SR2), by reprobing of blots (Fig. 4). Our preli-
minary work showed that the combination of SR1
and SR2 rather than individual antagonist use is typi-
cally needed to antagonize HU-210 effectively in
immune cells. No significant change was observed
in total MAPK42/44 immunoreactivity (ODavg =
0.20  0.03) whereas pMAPK42/44 was increased in
the presence of cytokines, potentially reflecting CB
receptor response to cytokine stimulation in PBMC.
These levels were decreased close to basal levels
(ODavg = 0.21  0.05) in the presence of SR1 and
SR2 (Fig. 4). TNF-a induced the highest level of
(a) (b)
Figure 2 (a–b) CB1 and CB2 protein
expression determined by flow cytome-
try. Changes were measured as increase
in mean fluorescence intensity (MFI) of
gated lymphocytes/monocytes (a) CB1
and CB2 in whole blood (left panel). (b)
CB1 and CB2 in PBMC (right panel).
See, text for significance levels. Results
shown are representative of five indepen-
dent experiments. Control = rabbit IgG.
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pMAPK42/44 immunoreactivity (ODavg = 0.72 
0.14; P = 0.03); SR1/SR2 reduced it (ODavg = 0.53 
0.08; P = 0.04) while remaining above basal levels.
Beta-actin immunoreactivity remained unchanged.
CB1 and CB2 immunoreactivity and functional response
in cytokine-stimulated PBMC
CB1 and CB2 immunoreactivity was assessed by Wes-
tern blot in cytokine-stimulated PBMC with or with-
out the cannabinoid receptor antagonists SR141716A
(SR1) and SR144528 (SR2) (300 nM each). Two
bands were detected at around 60 and 37 kDa possi-
bly corresponding to CB1 dimer and monomer, respec-
tively, and a band migrating at approx. 60 kDa
representing CB2 monomer (Fig. 5). These band sizes
were similar to those obtained in the previous litera-
ture (Nunez et al. 2004, De Jesus et al. 2006) and to
those of reference human CB1 recombinant protein
(Fig. 5, left lane). CB1 and CB2 protein expression
was upregulated by exposure to cytokines and down-
regulated in the presence of SR1 and SR2. The maxi-
mum OD increase was 55% (P = 0.02) for CB1 and
17% for CB2 (P = 0.07), possibly because of a higher
baseline expression of CB2. No significant changes
were observed in beta-actin immunoreactivity.
Effect of NF-kB inhibitor treatment on cannabinoid
receptor and TNF-a gene expression in PBMC
NF-jB is a key transcription factor for several inflam-
matory mediators including TNF-a. Given that this
cytokine induced the highest levels of CB1 and CB2
expression (see above), we investigated its influence on
cannabinoid receptor and TNF-a gene expression in
PBMC unstimulated or stimulated with TNF-a, in the
presence or absence of the NF-jB inhibitor SN50
(18 lM). SN50 significantly decreased the levels of CB1,
CB2 and TNF-a mRNA (P = 0.004, P = 0.002 and
P = 0.004, respectively) compared to those of unstimu-
lated cells and also decreased their expression in TNF-
a-stimulated PBMC (all P < 0.05) (Fig. 6). These
results indicate that TNF-a induction of CB1, CB2 and
TNF-a itself involves the NF-jB signalling pathways.
Cytokine, CB1 and CB2 mRNA expression in blood from
MS patients
mRNA levels for IL-6, IL-1b and TNF-a were signifi-
cantly increased in patient with MS blood compared to
that of controls. IL-6 showed the largest increase
(a)
(b)
(c)
(d)
Figure 3 (a) Densitometry measurements in phosphorylated
(p)ERK response to stimulation. Response of PBMCs to FCS
2 and 10%, followed by a time-dependent (5–20 min)
response to 100 nM HU-210. The 2 vs. 10% FCS on these
blots demonstrates a well-established upregulation of pERK
by high concentrations of FCS. The difference between the
average OD of pERK at 15-min stimulation was statistically
significant compared with 2% FCS (P = 0.03, n = 3 experi-
ments, indicated with asterisk). The highest level of pERK
with exposure to 100 nM HU-210 was observed after 15 min
(average OD = 0.25  0.08) with a 23% increase (b) Phos-
phorylated ERK 42/44 (pERK, 42 kDa) and (c) Total Erk
42/44 (Erk) (d) Beta-actin was used as housekeeping protein;
levels remained unchanged.
(a)
(b)
(c)
(d)
Figure 4 Immunoreactivity for pErk 42/44 and effects of
cytokine treatment in PBMC. (a) Densitometry measurements
from three experiments. TNF-a-stimulated cells express sig-
nificantly higher pErk levels than unstimulated cells or TNF-
a-stimulated cells in the presence of SR1 and 2 NF-kB inhibi-
tors, as indicated by asterisk. At 42 kDa, TNF-a induced an
increase in pErk levels (OD avg = 0.72  0.14; P = 0.03)
compared to unstimulated samples, and its effects were
reduced synergistically by SR1 and SR2 (OD
avg = 0.53  0.08; 26%; P = 0.04). t-test for independent
samples with P < 0.05; n = 3. (b) Bands corresponding to
pErk 42/44 were detected while (c) only bands at 42 kDa
were detected for total Erk (ErK); this showed no significant
change. (d) b-actin showed no significant change.
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(17-fold; P = 0.01) in the MS group while IL-1b
showed fivefold (P = 0.02) and TNF-a showed six-
fold (P = 0.01) increase (Fig. 7a). CB1 and CB2 mRNA
were also significantly elevated in MS blood compared
to that of controls. CB1 and CB2 gene expression was
increased approximately four- (P = 0.02) and fivefold
(P = 0.01), respectively, in patients with MS (Fig. 7b).
CB1 and CB2 mRNA and protein expression in MS vs.
healthy control cytokine-stimulated PBMC
To compare inducibility of CB receptors by cytokines
in normal human immune cells and those of patients
with MS, we investigated the effects of IL-1b, IL-6
and TNF-a on CB mRNA of PBMC from 12 normal
control subjects and 12 age- and sex-matched patients
with MS. We used low concentration ranges (100 pg
mL1) that are close to those found in body fluids in
inflammatory circumstances. In this sample, the same
trends as with the higher concentrations used above in
normal controls were noted (data not shown). Statisti-
(a1)
(b1)
(a2)
(b2)
Figure 5 (a) a1. Densitometry graph of the Western blots
(n = 3) for CB1 at 60 kDa. a2. Western blots showing immu-
noreactivity to CB1 antibody. Bands were detected at 32 (not
shown) and 60 kDa corresponding to CB1. Lower blot (a2)
is the corresponding b-actin. (b) b1. Densitometry graph of
the Western blots (n = 3) for CB2. b2 shows 60 kDa band
for CB2 and below; lower blot (b) is its corresponding b-
actin. TNF-a increased CB2 levels (OD avg = 0.34  0.07;
17% increase), which was reduced in the presence of recep-
tor antagonists (OD avg = 0.27  0.07). TNF-a increased
CB1 (OD avg = 0.65  0.13; 55% increase; P < 0.025). No
changes in corresponding b-actin were observed.
Figure 6 Effects of NF-jB inhibitor SN50 [18 lM] on CB1(left), CB2 (middle) and TNF-a (right) mRNA in unstimulated and
TNF-a- stimulated PBMC. The NF-jB inhibitor (SN50) decreased expression levels of each gene by more than a half in TNF-a-
stimulated PBMC. Data represent mean average SEM; n = 4. t-test *= P < 0.05; **P < 0.005.
(a)
(b)
Figure 7 Cytokine and cannabinoid receptor mRNA results
were based on normalized ratio of mean mRNA to mean
RPLPO gene. (a) TNF-a, IL-6, IL-1b and cannabinoid recep-
tors (b) CB1 and CB2 mRNA expression measured by qPCR
in control (n = 19) vs. MS (n = 20) blood. Data are
displayed as mean  SEM of 3–4 experiments. Asterisks
(*) = P < 0.025 unpaired Student’s t-test.
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cal significance and a trend is seen for CB1 and CB2
increase at baseline in patients with MS (P = 0.04 and
0.07 respectively). IL-6 increased both CB1 and CB2
mRNA in healthy controls (P = 0.018 and 0.013
respectively). The results partially confirm those using
higher cytokine concentrations, but indicate that the
lower concentrations are less potent. The data suggest
that MS patients’ PBMC tend to respond similarly to
those of healthy subjects in terms of CB induction,
however, starting from higher baseline expression lev-
els. No significant differences were noted between
untreated patients and those on immunomodulatory
treatment.
At the protein levels, similar trends were observed.
Significance was noted in CB2 levels being higher in
all cytokine-stimulated PBMC of MS than in healthy
controls (Fig. 8).
Discussion
Our study contributes to the evidence that the inter-
action between the cannabinoid system and the cyto-
kine network is bidirectional (Roche et al. 2008,
Rubio-Araiz et al. 2008) and extends this evidence
to human biology. CB1 and CB2 expression levels
were most significantly induced by TNF-a. This
occurs, at least in part, through NF-jB activation as
its inhibition suppressed TNF-a-enhanced CB1, CB2
as well as TNF-a gene expression itself. Activation
of NF-jB could have been induced by stimulation of
the TNF receptor. Upon activation, NF-jB translo-
cates to the nucleus where it binds DNA and trig-
gers the transcription of target genes (Ledeboer et al.
2005), some of which encode inflammatory proteins
and may also include the cannabinoid receptor
genes. It has been shown that the CB receptors
are involved in TNF-a-mediated NF-jB activation
(Zheng et al. 2008). NF-jB mediates the TNF-a-
induced transcription of CB1 gene in neurones (Born-
er et al. 2012). Thus, cytokine-responsive cells such
as T cells, macrophages, neurones, astrocytes and
microglia may enhance CB1 and CB2 expression
through the NF-jB pathway. A study by B€orner
et al. (2007) provides support for this, showing that
the activation of human T cells upregulates CB1 but
not CB2, transcription, and that CD3/CD28-mediated
upregulation is in part NF-jB dependent through
activation of CB1 promoter.
Figure 8 CB1 and CB2 expression, represented as median fluorescence intensity (left panel) in PBMC from 12 healthy controls
and 12 MS patients under the specified stimulation conditions. Data are shown for lymphocyte/monocyte-gated cells. The right
panel is a representative histogram of CB1 and CB2 expression in an MS patient’s PBMCs in different stimulation conditions.
Colour legend, Black: Isotype Control; Red: Unstimulated; orange: +IL-1b; blue: +IL-6; pink: +TNF-a. Results show a statisti-
cally significant increase in CB2 expression between controls and MS patients after stimulation with IL-1b, IL-6, and TNF-a.
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On the other hand, caution is invited in interpreta-
tion of our results, as SN50 may not be highly specific
for NF-jB, being also a proteasome and AP-1 inhibi-
tor (Boothby 2001). Of note, in a separate but similar
experimental set-up, we were unable to block the
induction of CB1 and CB2 in the presence of AP-1
inhibitor NGDA, suggesting at least that the effect of
SN50 was not due to AP-1 blockade (Jean-Gilles L,
Constantinescu CS, unpublished observations).
Activation of MAPK reflects CB receptor activity.
Recently, CB2 was shown to be upregulated by stimu-
lation with IL-1b, TNF-a or lipopolysaccharide in
synovial fibroblasts of patients with rheumatoid
arthritis, and the selective CB2 agonist HU-308
inhibited IL-1b-induced production of IL-6 and
IL-1b-induced activation of Erk 1/2 and p38 MAPK
(Gui et al. 2014). In our study, the upregulation of
CB1 and CB2 mRNA and protein was paralleled by
activation of MAPK upon exposure to pro-inflamma-
tory cytokines. This confirms that the upregulation of
CB receptors in immune cells has functional conse-
quences. However, the similarity of MAPK activation
by cannabinoid receptor activation and by inflamma-
tory cytokines in PBMC does not necessarily imply
that these phenomena are causally linked.
Our finding of upregulation of CB by inflammatory
cytokines and in MS, together with the dysregulation
of the endocannabinoid system in MS (Jean-Gilles
et al. 2009), raises the possibility of a therapeutic
effect of cannabinoids in inflammatory diseases.
We show that cannabinoid receptors are functional
in PBMC, as stimulation with HU-210-enhanced
phosphorylation of MAPK 42/44 (also known as
ERK1/2). Cannabinoids have previously been shown
to activate these kinases through the activation of can-
nabinoid receptors (Upham et al. 2003). The fact that
exposure of cytokine-stimulated cells to cannabinoid
receptor antagonists, SR1 and SR2 synergistically sup-
pressed the functional response of the cannabinoid
receptors to cytokines suggests that these responses
were direct and specific.
The present study also demonstrates that CB1 and
CB2 upregulation in the blood of patients with MS.
This is in line with very recent data by Sanchez Lopez
et al. (2015) which shows an increased expression of
cannabinoid receptors in peripheral blood lympho-
cytes from patients with MS. Of note, in the second
set of experiments comparing PBMC from healthy
controls and patients with MS, the upregulation in
MS was less prominent. The difference from baseline
levels in Figure 7b may represent difference between
whole blood and PBMC expression. This may also
reflect the use of frozen cells (3–5 months) or the
blunting of the overall expression due to the 58% of
patients being on disease-modifying treatments, as
interferon treatment reduces CB levels (Sanchez Lopez
et al. 2015). In our study, there is baseline variation
in the levels of expression of these receptors, and
some discrepancies between results at the mRNA and
protein level; between results of whole blood testing
vs. PBMC; and between results using higher vs. lower
cytokine concentrations. Regulation of expression at
the protein and mRNA level can differ, in particular
for cytokines, through post-translational or mRNA
stability changes (e.g. Kazanecki et al. 2007). Never-
theless, the tendency towards an increase in CB
expression by cytokines and an increase in MS com-
pared to controls was reasonably consistent at the
mRNA, protein and signalling level. The responses of
immune cells of patients with MS to inflammatory
cytokines, while, in some instances, more vigorous
than those of controls, tend to be similar. This was
also observed in immune cell subsets of a separate set
of patients with MS vs. controls (n = 5 and 3, respec-
tively) (data not shown); however, the small sample
size precludes definitive conclusions.
Upregulation of CB in MS is associated with a
simultaneous upregulation of pro-inflammatory cyto-
kine expression in immune cells as previously demon-
strated in MS mouse models (Maresz et al. 2005,
Lorıa et al. 2008). Our current findings are consistent
with previous reports demonstrating that pro-inflam-
matory cytokines are upregulated in patients with MS
(Kahl et al. 2002, Filion et al. 2003).
We recognize that the association of the upregula-
tion of CB1 and CB2 to that of cytokines in MS does
not imply causation, in particular as concentration of
cytokines likely to be found in body fluids in MS was
less potent than the doses used in vitro on control
cells in the first part of the study. The increased
expression of CB1 and CB2 in MS may be in part
mediated by individual pro-inflammatory cytokines or
their combined effect. In addition, other factors in the
MS blood or inflammatory/neurodegenerative micro-
environment may also contribute to CB upregulation,
as a more general damage signal. Endocannabinoids
themselves can upregulate their own receptors. We
have previously demonstrated upregulation of endoc-
annabinoid levels in blood (Jean-Gilles et al. 2009),
which can contribute to CB1 and CB2 upregulation.
This study is among the first thorough investiga-
tions of cannabinoid receptor regulation by prototypi-
cal, antigen-presenting cell-derived pro-inflammatory
cytokines in humans and of their expression in MS
blood. Further investigations are required to better
understand the mechanisms entailed in CB1 and CB2
receptor regulation by cytokines, including studies to
determine whether there is a direct transcriptional
effect of these cytokines on the CB receptor genes as
shown for transcriptional control of the CB1 gene by
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IL-4 (Borner et al. 2008). Further investigations in MS
patients, in different phases of MS with different levels
of disease activity and under different treatments, will
also be important. Very recently, it was shown that
untreated patients with MS have increased gene
expression levels of cannabinoid receptors in different
types of immune cells, and those levels decrease signif-
icantly over the course of 1 year of interferon-beta
(IFN-b) treatment (Sanchez Lopez et al. 2015). This
observation is consistent with our findings, given the
suppressive effect of IFN-b on proinflammatory cyto-
kines.
There may be potential limitations of our study.
The specificity of CB1 and CB2 antibodies used in the
first part of the study has been subject to some
debate, in part explaining some of the discrepancies
found in the literature (Grimsey et al. 2008). How-
ever, well-conducted human studies have detected
bands of the same size as in our Western blots, nota-
bly De Jesus et al. (2006), who detected pronounced
bands of 60 and 37 kDa ascribed to CB1 (the latter
potentially representing a result of deglycosylation or
proteolysis of the latter); these bands were confirmed
in other studies, for example Xu et al. (2005). For
CB2, a 60 kDa band has also been confirmed, for
example by Nunez et al. (2004). In addition, in preli-
minary studies, we showed significant suppression of
both CB1 and CB2 positivity by an average of 74%
after blocking with recombinant CB1 and CB2 (data
not shown). This indicates that the antibodies used
here were specific. It must be noted that densitometry
on Western blots performed with HRP reaction, while
not fully quantitative, allows for comparisons within
experiments.
The lower cytokine concentrations were less potent
than the high concentrations used initially. We need
to take into account the fact that the in vivo inflam-
matory environment is much more complex and com-
bination of lower concentrations may have similar
effects to individual higher concentrations in vitro.
For example, cytokines are known to influence the
expression of one another and a multitude of other
immune factors could further modulate the expression
levels of cytokines or cannabinoid receptors. This is in
part the reason we included experiments on whole
blood in this study, to reproduce better the in vivo
conditions and to minimize alterations that may result
from cell separation. Indeed, there were differences
between whole blood and PBMC results, which can
be explained by the different micro-environment.
Thus, caveats of translating in vitro results to the
complex in vivo context must be taken into consider-
ation.
There may be multiple functional implications of
the CB regulation by inflammatory cytokines in
particular TNF-a, but also IL-6 and IL-1. As well as
cannabinoids themselves, these cytokines have both
pro- and anti-inflammatory properties, depending on
a variety of factors including concentration, micro-
environment, timing of appearance and clearance.
TNF-a has both neuroprotective and neurodegenera-
tive effects. Such dual effects are also thought to
exist in CB signalling. Interesting data show a high
level of coregulation between TNF-a and cannabinoid
receptors in the CNS, in the process of neural stem
cell migration. TNF-a provides a crucial signal for
stem cell migration, and this signal appears to be
dependent on CB1/CB2 signalling (Rubio-Araiz et al.
2008). Our data provide a plausible mechanistic
explanation for this important biological phenome-
non, whereby TNF-a induces the required CB1 and
CB2 expression.
Previous studies have shown analgesic effects of CB
agonists in neuropathic, but not normal, rats (Sagar
et al. 2005). Upregulated CB1 expression in these ani-
mals contributes to increased analgesic efficacy of
cannabinoids (Siegling et al. 2001). Moreover, CB2-
mediated control of neuropathic pain in mice is IFN-c
dependent (Racz et al. 2008). Also, it has been
shown that expression of endocannabinoid ligands is
increased in a viral model of MS and inflammatory
lesions of patients with MS (Eljaschewitsch et al.
2006, Lorıa et al. 2008) and in plasma of patients
with different types of MS (Jean-Gilles et al. 2009).
Such studies may help to elucidate cannabinoid mech-
anisms involved in controlling MS symptoms such as
spasticity, overactive bladder and pain. In addition,
polymorphisms in the CB genes have been associated
both with MS subtypes and with surface CB expres-
sion (Woolmore et al. 2008, Ramil et al. 2010, Rossi
et al. 2013). This may explain the heterogeneity at
baseline and upon stimulation in our study. Future
studies may determine which patients with MS are
most likely to show benefit from modulation of the
cannabinoid system. If the regulation of cannabinoid
receptors in CNS cells and immune cells is similar,
our results could contribute to the future studies of
cannabinoid neuroprotective mechanisms and possibly
future treatment of inflammatory and neurodegenera-
tive diseases.
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